Listing Nasdaq Stockholm 2021
Isofol announced on October 21 that the Company’s shares are admitted to trading on Nasdaq Stockholm. The shares of the Company will be traded with unchanged ticker ISOFOL and ISIN-code (SE0009581051). No new shares will be issued in connection with the shares being admitted to trading on Nasdaq Stockholm and the Company’s shareholders do not need to take any actions in connection with the listing.
2021-10-29 Redeye – interview with Isofol’s CEO, Ulf Jungnelius, in connection with the list change to Nasdaq Stockholm. (In Swedish)
2021-10-25 Video clips, produced by Nasdaq Stockholm, during the digital uplisting ceremony.
2021-10-21 Pareto Securities – interview with Isofol’s CEO, Ulf Jungnelius, in connection with the list change to Nasdaq Stockholm. (In Swedish)
2021-10-21 Ulf Jungnelius, CEO, rings the Nasdaq bell when Isofol’s share is listed on Nasdaq Stockholm.
“Listing on the Main Market will raise awareness among investors about Isofol’s drug development within oncology. The listing will strengthen our profile and our brand on the market and enhance the opportunities to receive access to Swedish and international capital markets. Moreover, the listing is a seal of approval for our organization and operation. It also creates the opportunity for increased visibility and transparency and has possibility to result in increased liquidity for the share and may thereby create additional value for our shareholders” says Ulf Jungnelius, CEO of Isofol.
● The first day of trading on Nasdaq Stockholm Main Market is expected to be on October 21, 2021
● The last day of trading on Nasdaq First North Premier Growth Market is expected to be on October 20, 2021
● The shares will continue to be traded under the same ticker (ISOFOL) and ISIN code (SE0009581051)
● No new shares will be issued in connection with the list change
● The shareholders in Isofol do not need to take any actions in connection with the list change
Isofol has engaged Advokatfirman Vinge KB as legal advisor and Carnegie Investment Bank AB (publ) as financial advisor in connection with the listing on Nasdaq Stockholm.
Press releases and Prospect
|2021-10-15 Isofol Medical AB (publ) intends to list…||71 kB|
|2021-10-18 Isofol Medical AB (publ) publishes prospectus…||110 kB||Un-authorized translation of the Swedish prospect|
|2021-10-18 Isofol Medical AB (publ) Prospekt Nasdaq Stockholm (SWE)||1,8 Mb||Isofol Medical AB (publ) Prospect Nasdaq Stockholm (ENG)||2 Mb|
|2021-10-21 Isofol Medical AB (publ) Trading in Isofol´s shares commences today…||69 kB|
The prospectus is also available on the Swedish Financial Supervisory Authority’s (Sw. Finansinspektionen) website, www.fi.se.